New data released ahead of the American Society of Clinical Oncology (ASCO) meeting confirms Roche’s strong position in a new class of B-cell non-Hodgkin’s lymphoma (NHL) therapies – but also makes clear that it faces tough competition from rivals Genmab and AbbVie.
Roche has not one, but two, CD3xCD20s bispecific antibody candidates in late-stage development for non-Hodgkin’s lymphoma, mosunetuzumab and glofitamab, both...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
